Overview

Established in 1996, the Hematology Department is dedicated to the diagnosis and treatment of a wide range of hematological diseases. Over the years, we have gained extensive clinical experience, particularly in targeted therapy and chemotherapy for patients with malignant lymphoma. We are also deeply involved in molecular biological diagnosis and targeted treatment of multiple myeloma.

Expert Team

Our Hematology Department is comprised of a skilled team of 6 clinical physicians, including 1 associate chief physician. Our team is committed to delivering high-quality care and advancing the field through both clinical practice and research.

Services

We specialize in the diagnosis and treatment of complex hematological conditions. Our focus includes leukemia, myelodysplastic syndrome, malignant lymphoma, benign and malignant anemias, and thrombocytopenia. Our expertise in targeted therapy and chemotherapy, especially for malignant lymphoma, has led to significant clinical success. We are also leaders in the molecular biological diagnosis and targeted treatment of multiple myeloma.

Innovations & Achievements

Since 2016, our department has been at the forefront of clinical research on Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy in China, achieving notable therapeutic effects. Our innovative approach in this field highlights our commitment to pioneering advanced treatments for hematological diseases.

Education & Research

We play a crucial role in medical education, providing undergraduate and graduate training for students from Tongji University, Dalian Medical University, and Shanxi Medical University. As a teaching base for standardized physician training in internal medicine in Shanghai, we also conduct training for the American Heart Association’s Basic and Advanced Life Support courses. Our faculty members have been repeatedly recognized as Outstanding Teaching Instructors in Shanghai.

Academic Achievements

With a focus on myelodysplastic syndrome and multiple myeloma, our department has undertaken 7 research programs at the provincial and ministerial levels in the past five years. We have published nearly 30 SCI papers and core journal articles both domestically and internationally. Additionally, our team has contributed to the compilation of 5 hematology monographs, furthering our impact on the field.